Trial reportAnnals of clinical and translational neurology2023
Baseline characteristics of the North American prodromal Synucleinopathy cohort.
Trial report in Annals of clinical and translational neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 44 citations in OpenAlex.
- The Prodromal Synucleinopathy Rating Scale: An Assessment in Patients With REM Sleep Behavior Disorder.Neurology · 2026Observational
- Discordance Between Striatal Dopaminergic Imaging and Motor Performances in REM Sleep Behavior Disorder.Neurology open access · 2026Article
- Genetic associations between post-traumatic stress disorder and REM-sleep behavior disorder.NPJ Parkinson's disease · 2026Article
- Prodromal Lewy Body Disorder Features in REM Sleep Behavior Disorder With Biomarker-Defined Synucleinopathy.Annals of clinical and translational neurology · 2026Article
- REM Sleep Behavior Disorder as a Key Predictor of Cognitive Decline: Insights from a Narrative Review.Sleep science (Sao Paulo, Brazil) · 2026Review
- Sex differences in clinical and prognostic trajectories in patients with idiopathic REM sleep behavior disorder: Insights from the FARPRESTO cohort.Journal of Parkinson's disease · 2026Article
- The North American Prodromal Synucleinopathy study: protocol for a multi-site, longitudinal, observational study of idiopathic/isolated rapid eye movement sleep behavior disorder.Sleep advances : a journal of the Sleep Research Society · 2026Article
- Heart rate variability impairment during sleep in Veterans with rapid eye movement sleep behaviour disorder, traumatic brain injury, and post-traumatic stress disorder: an early potential window into autonomic dysfunction?Journal of sleep research · 2025Article
- Self-testing for symptoms and signs of prodromal alpha-synucleinopathies: results from the Tasmanian ISLAND Sleep Study.GeroScience · 2025Article
- REM Sleep Behavior Disorder as a Prodromal Synucleinopathy: Updates on Clinical and Laboratory Biomarkers, and Implications for Neuroprotective Trials.Current neurology and neuroscience reports · 2025Review
- Estrogen-related receptor gene expression associates with sex differences in cortical atrophy in isolated REM sleep behavior disorder.Nature communications · 2025Article
- The Future of Parasomnias.Journal of sleep research · 2025Review
- Characterizing Parkinson's Disease Clinical and Biomarker Interactions in REM Sleep Behavior Disorder.medRxiv : the preprint server for health sciences · 2025Article
- Nigral volume loss in prodromal, early, and moderate Parkinson's disease.NPJ Parkinson's disease · 2025Article
- Phenoconversion in Women and Men With Isolated REM Sleep Behavior Disorder: A Retrospective Cohort Study.Neurology · 2024Article
- IGLON5 Frequency in Idiopathic REM Sleep Behavior Disorder: A Multicenter Study.Neurology(R) neuroimmunology & neuroinflammation · 2024Article
- Cardiovascular Implications of Sleep Disorders Beyond Sleep Apnea.Current sleep medicine reports · 2024Article
- Article
- Validation of the RBD Symptom Severity Scale in the North American Prodromal Synucleinopathy Consortium.Neurology · 2024Article
- Contemporary diagnostic visual and automated polysomnographic REM sleep without atonia thresholds in isolated REM sleep behavior disorder.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 14 institutions in 2 countries.
Funding
Abstract
objectiveRapid eye movement (REM) sleep behavior disorder (RBD) is widely considered a prodromal synucleinopathy, as most with RBD develop overt synucleinopathy within ~10 years. Accordingly, RBD offers an opportunity to test potential treatments at the earliest stages of synucleinopathy. The North American Prodromal Synucleinopathy (NAPS) Consortium has created a multisite RBD participant, primarily clinic-based cohort to better understand characteristics at diagnosis, and in future work, identify predictors of phenoconversion, develop synucleinopathy biomarkers, and enable early stage clinical trial enrollment.
methodsParticipants ≥18 years of age with overnight polysomnogram-confirmed RBD without Parkinson's disease, dementia, multiple system atrophy, or narcolepsy were enrolled from nine sites across North America (8/2018 to 4/2021). Data collection included family/personal history of RBD and standardized assessments of cognitive, motor, sensory, and autonomic function.
resultsOutcomes are primarily reported based on sex (361 total: n = 295 male, n = 66 female), and secondarily based on history of antidepressant use (n = 200 with, n = 154 without; with correction for sex differences) and based on extent of synucleinopathy burden (n = 56 defined as isolated RBD, n = 305 defined as RBD+ [i.e., exhibiting ≥1 abnormality]). Overall, these participants commonly demonstrated abnormalities in global cognition (MoCA; 38%), motor function (alternate tap test; 48%), sensory (BSIT; 57%), autonomic function (orthostatic hypotension, 38.8%), and anxiety/depression (BAI and PHQ-9; 39.3% and 31%, respectively).
interpretationThese RBD participants, assessed with extensive history, demographic, cognitive, motor, sensory, and autonomic function demonstrated a lack of sex differences and high frequency of concomitant neurological abnormalities. These participants will be valuable for future longitudinal study and neuroprotective clinical trials.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.